Roy Buchanan
Stock Analyst at JMP Securities
(5.00)
# 11
Out of 5,090 analysts
71
Total ratings
53.62%
Success rate
101.23%
Average return
Main Sectors:
Stocks Rated by Roy Buchanan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CDTX Cidara Therapeutics | Maintains: Market Outperform | $153 → $173 | $220.36 | -21.49% | 8 | Oct 3, 2025 | |
| ASMB Assembly Biosciences | Initiates: Market Outperform | $38 | $35.01 | +8.54% | 1 | Sep 24, 2025 | |
| DVAX Dynavax Technologies | Reiterates: Market Outperform | $32 | $10.89 | +193.85% | 8 | Aug 22, 2025 | |
| ENTA Enanta Pharmaceuticals | Maintains: Market Outperform | $24 → $25 | $14.60 | +71.23% | 15 | Aug 12, 2025 | |
| PYPD PolyPid | Maintains: Market Outperform | $16 → $14 | $3.97 | +252.64% | 2 | Jun 17, 2025 | |
| CVAC CureVac | Reiterates: Market Outperform | $10 | $5.12 | +95.31% | 9 | May 28, 2025 | |
| ANTX AN2 Therapeutics | Maintains: Market Outperform | $5 → $2 | $1.10 | +81.82% | 9 | May 5, 2025 | |
| INO Inovio Pharmaceuticals | Reiterates: Market Outperform | $18 | $2.07 | +769.57% | 3 | Mar 14, 2025 | |
| TPG TPG Inc. | Reiterates: Market Perform | n/a | $61.69 | - | 1 | Feb 13, 2025 | |
| ESPR Esperion Therapeutics | Reiterates: Market Outperform | $7 → $4 | $3.73 | +7.24% | 3 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $23 → $14 | $3.48 | +302.30% | 1 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $33 | $114.51 | -71.18% | 1 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $4 → $5 | $4.42 | +13.12% | 5 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $443 → $448 | $901.17 | -50.29% | 2 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $14 → $16 | $10.56 | +51.52% | 1 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.20 | - | 2 | Feb 16, 2023 |
Cidara Therapeutics
Oct 3, 2025
Maintains: Market Outperform
Price Target: $153 → $173
Current: $220.36
Upside: -21.49%
Assembly Biosciences
Sep 24, 2025
Initiates: Market Outperform
Price Target: $38
Current: $35.01
Upside: +8.54%
Dynavax Technologies
Aug 22, 2025
Reiterates: Market Outperform
Price Target: $32
Current: $10.89
Upside: +193.85%
Enanta Pharmaceuticals
Aug 12, 2025
Maintains: Market Outperform
Price Target: $24 → $25
Current: $14.60
Upside: +71.23%
PolyPid
Jun 17, 2025
Maintains: Market Outperform
Price Target: $16 → $14
Current: $3.97
Upside: +252.64%
CureVac
May 28, 2025
Reiterates: Market Outperform
Price Target: $10
Current: $5.12
Upside: +95.31%
AN2 Therapeutics
May 5, 2025
Maintains: Market Outperform
Price Target: $5 → $2
Current: $1.10
Upside: +81.82%
Inovio Pharmaceuticals
Mar 14, 2025
Reiterates: Market Outperform
Price Target: $18
Current: $2.07
Upside: +769.57%
TPG Inc.
Feb 13, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $61.69
Upside: -
Esperion Therapeutics
Feb 11, 2025
Reiterates: Market Outperform
Price Target: $7 → $4
Current: $3.73
Upside: +7.24%
Jan 30, 2025
Maintains: Market Outperform
Price Target: $23 → $14
Current: $3.48
Upside: +302.30%
Jan 10, 2025
Reiterates: Market Outperform
Price Target: $33
Current: $114.51
Upside: -71.18%
Aug 2, 2024
Maintains: Market Outperform
Price Target: $4 → $5
Current: $4.42
Upside: +13.12%
Mar 3, 2023
Maintains: Market Outperform
Price Target: $443 → $448
Current: $901.17
Upside: -50.29%
Mar 1, 2023
Maintains: Market Perform
Price Target: $14 → $16
Current: $10.56
Upside: +51.52%
Feb 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $1.20
Upside: -